Business Context and Reporting Period
Company: Nova Measuring Instruments Ltd. (Nova)
Filing Type: Form 20-F (Annual Report)
Period Ended: December 31, 2008
Business Overview: Nova designs, develops, and produces integrated and stand-alone metrology systems for the semiconductor manufacturing industry. The company is incorporated in Israel and lists its ordinary shares on the Nasdaq Global Market and the Tel Aviv Stock Exchange. Its primary revenue source is the sale of process control systems for chemical mechanical polishing (CMP) and other semiconductor fabrication steps.
Key Financial Metrics (Year Ended Dec 31, 2008)
| Metric | 2008 (in thousands) | 2007 (in thousands) |
|---|---|---|
| Total Revenues | $38,969 | $58,077 |
| Gross Profit | $12,983 | $24,826 |
| Gross Margin | 33.3% | 42.8% |
| Operating Loss | $(6,958) | $(3,153) |
| Net Loss | $(5,421) | $(3,917) |
| Loss Per Share (Basic & Diluted) | $(0.28) | $(0.21) |
| Working Capital | $20,246 | $20,660 |
| Cash and Cash Equivalents | $19,325 | $15,324 |
| Total Assets | $35,791 | $48,385 |
| Shareholders' Equity | $22,341 | $27,584 |
Debt and Liquidity: The company reported no long-term debt as of December 31, 2008. Operating cash flow was negative at $(3.3) million in 2008, compared to positive $4.6 million in 2007. Management believes current cash reserves are sufficient to fund operations for at least the next 12 months.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased by 33% ($19.1 million) compared to 2007. Product sales revenue dropped 44% to $25.7 million, while service revenue increased 13.6% to $13.3 million.
- Margin Compression: Gross margin declined from 42.8% in 2007 to 33.3% in 2008. This was driven by lower product volumes and a $1.4 million inventory write-off (compared to $0.3 million in 2007).
- Operating Expenses: Total operating expenses decreased to $19.9 million from $28.0 million. Notably, Sales and Marketing expenses fell 26%, and General and Administrative expenses fell 34% due to reduced legal costs following the settlement of patent litigation. Research and Development expenses decreased slightly to $8.6 million.
- Impairment Losses: The company recorded a $0.6 million impairment loss related to HyperNex assets in 2008, down from $3.8 million in 2007. The HyperNex x-ray product group was closed in April 2008.
- Investment Gain: Net loss was partially offset by a $1.4 million gain from the repurchase of Auction Rate Securities at par value, reversing a 2007 impairment charge.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Guidance: Management anticipates continued difficult economic conditions in 2009 due to the global recession and a severe downturn in the semiconductor industry. Gartner forecasts a 46.1% decline in Wafer Fab Equipment sales for 2009. Nova plans to reduce aggregate operating expenses in 2009 relative to 2008. The company expects revenue opportunities to arise from technology buys for next-generation nodes (45nm and below) and retrofits to improve yield, though significant revenue growth is not assured.
Unusual Items:
- Inventory Write-off: $1.4 million recorded in Cost of Revenues due to decreased demand.
- Investment Gain: $1.4 million non-operating gain from the settlement of Auction Rate Securities.
Key Risks:
- Market Cyclicality: Heavy dependence on the cyclical semiconductor capital equipment market.
- Customer Concentration: The five largest customers accounted for 67% of revenues in 2008; the single largest customer accounted for 37%.
- Product Concentration: Substantial reliance on the integrated process control product line for chemical mechanical polishing.
- Delisting Risk: The company's share price fell below the $1.00 minimum requirement for Nasdaq listing. While temporary relief was granted through July 2009, failure to meet criteria could result in delisting.
- Geopolitical Risk: Operations are based in Israel, exposing the company to regional political and military instability.
Important Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the $19.3 million cash balance against the projected negative operating cash flow and the timeline for achieving profitability.
- Customer Concentration: Assess the risk associated with the top customer representing 37% of revenue and the potential impact of order cancellations or delays.
- Inventory Valuation: Review the $6.9 million inventory balance and the adequacy of provisions for obsolescence given the industry downturn.
- Nasdaq Compliance: Monitor the company's ability to regain compliance with Nasdaq listing standards (specifically the $1.00 minimum bid price) before the relief period expires.
- Government Grants: Note the contingent liability of approximately $8.2 million to the Israeli Office of the Chief Scientist for grants received, which must be repaid via royalties on future sales.